Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The self-assembling Lassa fever vaccine is a preclinical-stage vaccine candidate developed by the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. The vaccine utilizes a self-assembling platform designed to present Lassa virus antigens in a particulate or nanoparticle format. This approach is intended to enhance the immune response by mimicking the physical structure of a virus, potentially leading to more robust and durable protection against Lassa fever, a viral hemorrhagic fever endemic to parts of West Africa. The program is currently in the preclinical efficacy and safety stages of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on self-assembling Lassa fever vaccine.